Search the Newsreel

Urogen Pharma (URGN) to Announce Quarterly Earnings on Thursday

UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026

UroGen Pharma Ltd. will report its second-quarter 2026 financial results on Wednesday, August 5th, 2026, before the stock market opens. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. UroGen Pharma is a biotech company …

UroGen Pharma schedules Aug. 5 webcast before market open

UroGen Pharma (Nasdaq: URGN) announced it will report its second quarter 2026 financial results on Wednesday, August 5, 2026, before the U.S. stock market opens. The company will host a live audio webcast and conference call at 10:00 AM Eastern Time, which investors can …

Return on invested capital % of UroGen Pharma Ltd. – HAM:UR8

The article focuses on the "Return on invested capital %" for UroGen Pharma Ltd. (HAM:UR8). It appears to be a financial data page from TradingView, providing an overview of the company's financial performance metric. The content itself seems to be a template for displaying …

UroGen Pharma Ltd. Revenue Breakdown – HAM:UR8

UroGen Pharma Ltd. (HAM:UR8) generated €93.49 million in revenue last year, primarily from its RTGel Reverse Thermal Hydrogel segment, which contributed €93.48 million. The majority of this revenue came from Israel and the United States. This represents an increase from the previous year's total …

Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $42

Guggenheim has reiterated its Buy rating on UroGen Pharma Ltd (URGN.US) and increased its price target to $42. This signals continued confidence in the company's performance and future prospects from the investment firm.

What UroGen Pharma (URGN)'s UGN-501 IND Clearance Means For Shareholders

UroGen Pharma (URGN) recently received FDA clearance for its Investigational New Drug (IND) application for UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer, allowing a Phase 1 trial to commence. While this expands UroGen's uro-oncology pipeline, the article emphasizes that near-term focus …

Price to sales forward of UroGen Pharma Ltd. – NASDAQ:URGN

This article provides a brief financial update for UroGen Pharma Ltd. (NASDAQ: URGN), specifically focusing on its forward price-to-sales ratio. It indicates that the market was closed with no trades recorded at the time of the report. The content appears to be a stub …

UroGen Pharma (URGN) AGM 2026 Summary

UroGen Pharma's 2026 AGM highlighted the successful launch of ZUSDURI, a new FDA-approved bladder cancer treatment, and continued growth of JELMYTO. The meeting also addressed the advancement of pipeline products like UGN-103, UGN-104, and UGN-501, and nominated seven directors for election. Recent events emphasize …

Urogen Pharma stock hits 52-week high at 41.45 USD

Urogen Pharma's stock has reached a 52-week high of $41.45, reflecting strong investor confidence and significant year-to-date gains. The company has several positive developments, including an increased price target from Oppenheimer, a new patent for bladder cancer treatment, and FDA clearance for a Phase …

UroGen Pharma (URGN) Rallies On FDA Clearance As Valuation Questions Grow

UroGen Pharma (URGN) has seen its shares rally significantly after the FDA cleared its Investigational New Drug application for UGN-501, allowing a Phase 1 bladder cancer study. Despite strong recent share price performance, valuation questions arise with the most followed narrative suggesting it's 11% …

Short Sellers Are Betting Against UroGen Pharma Stock, But Wall Street Expects 263% Earnings Growth in 2027

UroGen Pharma (URGN) has experienced significant stock growth and strong technical indicators, with analysts predicting substantial revenue and earnings increases in the coming years. Despite this positive outlook and five years of revenue growth, the company remains unprofitable, leading to a notable level of …

Oppenheimer raises UroGen Pharma stock price target to $50 on sales outlook

Oppenheimer has increased its price target for UroGen Pharma (NASDAQ:URGN) to $50 from $40, maintaining an Outperform rating, based on increased sales projections for their Jelmyto product. The firm's updated estimates for Jelmyto sales in 2026-28 are $210 million, $448 million, and $648 million, …

H.C. Wainwright reiterates UroGen Pharma stock rating on patent news By Investing.com

H.C. Wainwright has reiterated a Buy rating and a $45.00 price target for UroGen Pharma (NASDAQ:URGN) after the company received a Notice of Allowance for a patent related to treating low-grade intermediate-risk non-muscle-invasive bladder cancer. This patent, supported by data from the ENVISION and …

Goldman Sachs Maintains UroGen Pharma Ltd(URGN.US) With Hold Rating, Raises Target Price to $44

Goldman Sachs has reiterated its Hold rating on UroGen Pharma Ltd (URGN.US) and has increased its price target for the company's stock to $44. This adjustment reflects a continued neutral stance on the company's prospects while revising the expected valuation upwards.

UroGen Pharma (URGN) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

UroGen Pharma (URGN) presented at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026, highlighting its RTGel technology for sustained drug delivery in urothelial cancer. The company discussed the commercial success of its products, JELMYTO and ZUSDURI, with ZUSDURI's expanded market reach and rapid uptake. …

UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103

UroGen Pharma Ltd. announced it received a U.S. patent allowance extending protection for ZUSDURI™ and investigational UGN-103 into July 2044. The patent covers methods for treating recurrent, low-grade intermediate-risk non-muscle-invasive bladder cancer without transurethral resection, utilizing UroGen's proprietary RTGel® technology. This strengthens the company's …

UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

UroGen Pharma Ltd. announced that the FDA has cleared its Investigational New Drug (IND) application for UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). This clearance allows the company to initiate a Phase 1 clinical study in Q4 2026 to evaluate …